Daily Respiratory Research Analysis
Analyzed 144 papers and selected 3 impactful papers.
Summary
Three standout studies advance respiratory science and care: a Nature Immunology multi-omics analysis identifies a pathogenic monocyte state linking immune dysregulation to pulmonary impairment in long COVID; a Science Translational Medicine study presents an escape-resistant RSV antibody cocktail with in vivo protection; and a Chest network meta-analysis clarifies that DPP-1 inhibitors and macrolides reduce exacerbations in non-cystic fibrosis bronchiectasis.
Research Themes
- Long COVID immunopathology and fibrotic signaling
- Escape-resistant antibody strategies against RSV
- Anti-inflammatory therapy optimization in bronchiectasis
Selected Articles
1. A distinct monocyte transcriptional state links systemic immune dysregulation to pulmonary impairment in long COVID.
Across multiple cohorts, a pathogenic monocyte state (LC-Mo) with TGFβ/WNT-β-catenin signaling and AP-1/NF-κB1-driven profibrotic programs correlated with fatigue and dyspnea and was elevated in those with severe respiratory symptoms. LC-Mo-like macrophages in BAL showed profibrotic profiles, and high LC-Mo associated with impaired interferon responses.
Impact: This work mechanistically links a defined immune cell state to persistent respiratory symptoms in long COVID and highlights actionable pathways (TGFβ, WNT-β-catenin) and impaired antiviral responses as potential targets.
Clinical Implications: LC-Mo features could serve as biomarkers to stratify long COVID patients with respiratory impairment and guide trials of immunomodulators (e.g., TGFβ/WNT pathway inhibitors or macrophage-targeted therapies) while monitoring interferon responsiveness.
Key Findings
- Identified a circulating monocyte transcriptional state (LC-Mo) enriched after mild–moderate acute infection with persistent elevation of CCL2, CXCL11, and TNF.
- LC-Mo exhibited TGFβ and WNT-β-catenin signaling with AP-1/NF-κB1-driven profibrotic programs; higher LC-Mo correlated with fatigue and dyspnea severity.
- BAL macrophages from patients with severe respiratory symptoms showed LC-Mo-like profibrotic profiles; high LC-Mo associated with impaired interferon responses after stimulation.
Methodological Strengths
- Integrated single-cell multiome with immunoprofiling across multiple cohorts
- Convergent validation using BAL samples and functional stimulation assays
Limitations
- Observational design limits causal inference
- Therapeutic targeting not tested prospectively in interventional trials
Future Directions: Prospective biomarker-driven trials testing TGFβ/WNT-β-catenin modulation or monocyte/macrophage-targeted therapies, with LC-Mo tracking and interferon response monitoring.
The mechanisms driving immune dysregulation in long COVID disease remain elusive. Here we integrated single-cell multiome data, immunological profiling and functional assays to investigate immune alterations across multiple cohorts. A transcriptional state in circulating monocytes (LC-Mo) was enriched in individuals with mild-moderate acute infection and accompanied by persistent elevations of plasma CCL2, CXCL11 and TNF. LC-Mo showed TGFβ and WNT-β-catenin signaling and correlated with fatigu
2. An antibody cocktail targeting conserved, nonoverlapping epitopes prevents viral escape and confers protection against RSV in vivo.
Two human antibodies bind conserved, nonoverlapping epitopes on RSV pre-F, jointly stabilizing the prefusion trimer and preventing conformational transitions. The 1A2/1B6 cocktail resisted in vitro viral escape over >20 passages and conferred in vivo protection, outperforming single antibodies and nirsevimab in escape assays.
Impact: Defines a structural and functional basis for an escape-resistant RSV antibody cocktail with demonstrated in vivo efficacy, informing next-generation prophylaxis/therapy.
Clinical Implications: Supports development of combination monoclonal prophylaxis for infants and high-risk groups, potentially improving breadth and durability over single-epitope targeting products.
Key Findings
- Cryo-EM revealed 1A2 and 1B6 bind conserved, nonoverlapping epitopes (sites IV/V and Ø/II/V) on RSV pre-F, stabilizing the prefusion trimer.
- The antibody cocktail resisted in vitro viral escape for >20 passages, unlike nirsevimab or single antibodies which selected escape mutations rapidly.
- In vivo studies demonstrated protective efficacy of the cocktail against RSV challenge.
Methodological Strengths
- Integrated structural biology (cryo-EM) with in vitro escape and in vivo efficacy studies
- Targeting conserved, nonoverlapping epitopes to minimize escape risk
Limitations
- Preclinical; no human pharmacokinetic, safety, or efficacy data yet
- Durability and breadth across diverse clinical RSV strains require further validation
Future Directions: Advance to clinical development with dose-finding and safety studies, evaluate breadth against circulating RSV lineages, and assess synergy with vaccines.
Respiratory syncytial virus (RSV) poses a critical threat to infants, yet vaccine and antibody development remains challenged by safety risks and antigenic variability. Here, we present a prophylactic strategy leveraging two human neutralizing antibodies, 1A2 and 1B6, which target distinct, conserved epitopes on the RSV prefusion F (pre-F) protein. Cryo-electron microscopy (cryo-EM) structural analysis revealed that 1A2 binds a "waist" epitope spanning antigenic sites IV/V, whereas 1B6 engages a
3. Efficacy of Anti-Inflammatory Therapies for Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and Network Meta-Analysis.
Across 31 trials (n=4,092), macrolides (RR 0.44) and DPP-1 inhibitors (RR 0.73) reduced overall exacerbations versus placebo; DPP-1 inhibitors also reduced severe exacerbations (RR 0.70). Benefits of DPP-1 inhibitors persisted irrespective of background macrolide use, and azithromycin showed the greatest reduction among macrolides.
Impact: Provides comparative, evidence-based guidance on anti-inflammatory strategies that reduce exacerbations in bronchiectasis, informing treatment selection and trial design.
Clinical Implications: Supports use of macrolides (especially azithromycin) or DPP-1 inhibitors for patients with frequent exacerbations, with attention to safety, antimicrobial stewardship, and patient phenotype.
Key Findings
- Macrolides reduced overall exacerbation frequency versus placebo (RR 0.44, 95% CI 0.35–0.56).
- DPP-1 inhibitors reduced overall (RR 0.73, 95% CI 0.60–0.88) and severe exacerbations (RR 0.70, 95% CI 0.54–0.89).
- DPP-1 inhibitor benefits were consistent regardless of long-term macrolide use; among macrolides, azithromycin had the largest effect (RR 0.37, 95% CI 0.29–0.48).
Methodological Strengths
- Network meta-analysis enabling indirect comparisons across eight anti-inflammatory agents
- Moderate-certainty estimates for key outcomes and subgroup consistency analyses
Limitations
- Heterogeneity in trial designs, durations, and patient phenotypes
- Limited power for some severe outcomes and safety subdomains
Future Directions: Head-to-head RCTs in defined phenotypes, real-world safety surveillance, and evaluation of combination or step-up strategies integrating DPP-1 inhibitors and macrolides.
BACKGROUND: Non-cystic fibrosis bronchiectasis (NCFB) is characterized by chronic respiratory symptoms and radiologic airway dilatation. Sustained neutrophilic inflammation is a key driver, prompting interest in anti-inflammatory pharmacotherapy as a new treatment paradigm; however, comparisons among anti-inflammatory agents are lacking. RESEARCH QUESTION: What is the current profile concerning efficacy and safety of anti-inflammatory therapies for bronchiectasis? STUDY DESIGN AND METHODS: We performed a syst